Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akero Therapeutics, Inc. - Common Stock (NQ:AKRO)

54.28 +0.34 (+0.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Akero Therapeutics, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Akero Therapeutics: Q4 Earnings Insights
Via Benzinga
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Akero Therapeutics Inc.
Via GlobeNewswire
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost. 
Via Investor's Business Daily
Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 100 points on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
11 Analysts Have This to Say About Akero Therapeutics
Via Benzinga
Akero Therapeutics: Q3 Earnings Insights
Via Benzinga
Why Akero Therapeutics Shares Are Slumping This Week
Akero's lead therapy fell short of its goals in a phase 2b trial to treat NASH. 
Via The Motley Fool
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of MercadoLibre, Inc. (NASDAQ: MELI) fell sharply during Friday’s session after the company reported fourth-quarter financial results. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Analyst Ratings for Akero Therapeutics
Via Benzinga
Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference
From Akero Therapeutics
Via GlobeNewswire
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance... 
Via Benzinga
E2open, Sharecare And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures traded higher this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Akero Therapeutics' Lead Candidate Potential: Analyst Unpacks Complicated Regulatory Path Forward
Tuesday, Akero Therapeutics Inc (NASDAQ: AKRO) reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to nonalcoholic... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Astra Space Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Tempest Therapeutics, Inc. (NASDAQ: TPST) shares jumped 1067% to $2.80 after the company released new data demonstrating superiority of TPST-1120 arm across multiple study endpoints in... 
Via Benzinga
Wegovy Maker Novo Nordisk, Akero Therapeutics, Eli Lilly, Athena Consumer Acquisition, Tesla: Why These 5 Stocks Are Trending Today
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 130 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Shares of 89bio Plummeted on Tuesday
So-so trial data for a competitor's NASH therapy candidate that is similar to 89bio's candidate spooked investors. 
Via The Motley Fool
Akero Therapeutics' Disappointing NASH Data Drags Its Rival
Earlier today, Akero Therapeutics Inc (NASDAQ: AKRO) reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to  
Via Benzinga
Crude Oil Moves Lower; Neogen Posts Downbeat Results
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 175 points on Tuesday. The Dow traded up 0.53% to 33,781.59 while the NASDAQ rose 0.72% to 13,581.64. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Big Pharma Could Transform Into BioTech Pharma
As the word itself says, biotechnology is simply technology based on biology. It uses the knowledge of cellular and biomolecular processes to develop technologies that improve our lives and overall... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Startek Shares Are Trading Higher By 29%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers SuperCom Ltd. (NASDAQ: SPCB) shares jumped 89% to $0.6805, after falling 13% on Monday. 
Via Benzinga
S&P 500 Rises 1%; US Wholesale Inventories Fall In August
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 250 points on Tuesday. The Dow traded up 0.81% to 33,876.62 while the NASDAQ rose 1.23% to 13,650.54. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Akero Therapeutics Stock Is Crashing Today
Investors are bailing on the biotech stock after disappointing clinical results for experimental NASH drug efruxifermin (EFX). 
Via The Motley Fool
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.